![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
Trial Results
August 16, 2022
Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
June 21, 2022
ECOG-ACRIN researchers presented a wide range of study results at the 2022 ASCO Annual Meeting
February 24, 2022
The first published results of a platform trial of PIK3CA mutations across multiple tumor types appear in the Journal of Clinical Oncology. The data are from the NCI-MATCH precision medicine trial.
January 26, 2022
A new post-surgery approach for treating HPV-related throat cancer uses less radiation safely and spares the majority of patients from chemotherapy
December 22, 2021
Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics
November 16, 2021
The phase III DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
July 7, 2021
Recent ECOG-ACRIN trial updates and results
May 28, 2021
Researchers with the ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present a wide range of research findings at the 2021 ASCO Annual Meeting
January 25, 2021
Dr. Sparano discusses the scientific and statistical collaboration behind a new tool, RSClin™, which integrates clinical–pathological and genomic risk information to guide adjuvant chemotherapy in node-negative breast cancer
October 19, 2020
The Journal of Clinical Oncology published new data from the NCI-MATCH precision medicine cancer trial that has broad relevance in medicine and provides a roadmap for future precision medicine trials
September 14, 2020
A second interim analysis of this international adjuvant study for HR+, HER2- early breast cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
July 29, 2020
Learn more about a less intense treatment that preserves throat function and spares unnecessary toxicities